Windtree Therapeutics (WINT) Competitors $1.13 -0.05 (-4.24%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. KZIA, ALLR, EVOK, PWUP, GLTO, GENE, ONVO, TTNP, PPBT, and CNSPShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Kazia Therapeutics (KZIA), Allarity Therapeutics (ALLR), Evoke Pharma (EVOK), PowerUp Acquisition (PWUP), Galecto (GLTO), Genetic Technologies (GENE), Organovo (ONVO), Titan Pharmaceuticals (TTNP), Purple Biotech (PPBT), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Kazia Therapeutics Allarity Therapeutics Evoke Pharma PowerUp Acquisition Galecto Genetic Technologies Organovo Titan Pharmaceuticals Purple Biotech CNS Pharmaceuticals Kazia Therapeutics (NASDAQ:KZIA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Do analysts recommend KZIA or WINT? Kazia Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 1,524.52%. Windtree Therapeutics has a consensus price target of $350.00, suggesting a potential upside of 30,873.45%. Given Windtree Therapeutics' higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than Kazia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor KZIA or WINT? In the previous week, Windtree Therapeutics had 2 more articles in the media than Kazia Therapeutics. MarketBeat recorded 3 mentions for Windtree Therapeutics and 1 mentions for Kazia Therapeutics. Kazia Therapeutics' average media sentiment score of 1.43 beat Windtree Therapeutics' score of 0.22 indicating that Kazia Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kazia Therapeutics Positive Windtree Therapeutics Neutral Do institutionals and insiders believe in KZIA or WINT? 30.9% of Kazia Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor KZIA or WINT? Kazia Therapeutics received 77 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 52.98% of users gave Kazia Therapeutics an outperform vote while only 42.86% of users gave Windtree Therapeutics an outperform vote. CompanyUnderperformOutperformKazia TherapeuticsOutperform Votes8052.98% Underperform Votes7147.02% Windtree TherapeuticsOutperform Votes342.86% Underperform Votes457.14% Which has better earnings and valuation, KZIA or WINT? Kazia Therapeutics has higher revenue and earnings than Windtree Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKazia Therapeutics$2.31M1.54-$17.56MN/AN/AWindtree TherapeuticsN/AN/A-$20.29M-$823.470.00 Which has more risk and volatility, KZIA or WINT? Kazia Therapeutics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Is KZIA or WINT more profitable? Kazia Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kazia TherapeuticsN/A N/A N/A Windtree Therapeutics N/A -362.76%-79.65% SummaryKazia Therapeutics beats Windtree Therapeutics on 12 of the 14 factors compared between the two stocks. Remove Ads Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$846,000.00$2.85B$5.28B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.0730.3821.6317.68Price / SalesN/A433.44371.0892.88Price / CashN/A168.6838.1534.64Price / Book0.113.416.373.94Net Income-$20.29M-$72.06M$3.20B$247.45M7 Day Performance-15.04%0.83%1.79%0.48%1 Month Performance-44.88%-18.82%-9.41%-7.08%1 Year Performance-99.70%-30.46%9.61%-0.35% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics1.7892 of 5 stars$1.13-4.2%$350.00+30,873.5%-99.7%$846,000.00N/A-0.0730Short Interest ↑News CoverageKZIAKazia Therapeutics3.6529 of 5 stars$0.71-0.1%$11.50+1,519.7%-76.4%$3.58M$2.31M0.0012Short Interest ↓Gap DownALLRAllarity Therapeutics0.3349 of 5 stars$0.80+0.6%N/A-98.6%$3.53MN/A0.0010Short Interest ↑EVOKEvoke Pharma0.3198 of 5 stars$2.35+4.4%N/A-63.2%$3.51M$10.25M-0.214Analyst ForecastShort Interest ↑Gap DownPWUPPowerUp AcquisitionN/A$0.45-16.5%N/A-94.7%$3.50MN/A0.00N/ANews CoverageHigh Trading VolumeGLTOGalecto2.4355 of 5 stars$2.55+0.4%$10.00+292.2%-85.0%$3.37MN/A-0.1340Short Interest ↑GENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading VolumeONVOOrganovo0.4965 of 5 stars$1.96-7.5%N/A-89.8%$3.33M$122,000.00-2.3120Short Interest ↑TTNPTitan Pharmaceuticals1.5049 of 5 stars$3.64-0.6%N/A-48.7%$3.33M$180,000.00-0.7010Short Interest ↓PPBTPurple Biotech2.2005 of 5 stars$2.49-3.5%$33.00+1,225.3%N/A$3.31MN/A-0.2820Gap DownCNSPCNS Pharmaceuticals1.4593 of 5 stars$1.12+1.8%$25.00+2,132.1%-99.8%$3.30MN/A-0.015Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies KZIA Competitors ALLR Competitors EVOK Competitors PWUP Competitors GLTO Competitors GENE Competitors ONVO Competitors TTNP Competitors PPBT Competitors CNSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCould this be the start of AI’s Second Wind?We're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy WINT Stock Free WINT Stock Alerts